BG107257A - Състави, съдържащи глюкокортикоидно средство за лечение на бронхо-белодробни заболявания - Google Patents

Състави, съдържащи глюкокортикоидно средство за лечение на бронхо-белодробни заболявания

Info

Publication number
BG107257A
BG107257A BG107257A BG10725702A BG107257A BG 107257 A BG107257 A BG 107257A BG 107257 A BG107257 A BG 107257A BG 10725702 A BG10725702 A BG 10725702A BG 107257 A BG107257 A BG 107257A
Authority
BG
Bulgaria
Prior art keywords
treatment
formulations containing
bronchopulmonary diseases
glucocorticoid drug
glucocorticoid
Prior art date
Application number
BG107257A
Other languages
English (en)
Inventor
David Lewis
David Ganderton
Brian Meakin
Gaetano Brambilla
Alessandra Ferraris
Original Assignee
Chiesi Farmaceutici S.P.A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici S.P.A filed Critical Chiesi Farmaceutici S.P.A
Publication of BG107257A publication Critical patent/BG107257A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Изобретението се отнася до състави за приложение чрез инхалатори с отмервана доза под налягане. Като активна съставка те съдържат глюкокортикоид, по-специално (22R)епимера на будезонид, в разтвор на хидрофлуоровъглероден пропелент, съразтворител и подходящо допълнително средство. Изобретението се отнася и до тяхното приложение за лечение на астма и други бронхо-белодробни заболявания.
BG107257A 2000-05-12 2002-11-08 Състави, съдържащи глюкокортикоидно средство за лечение на бронхо-белодробни заболявания BG107257A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2000MI001051A IT1318514B1 (it) 2000-05-12 2000-05-12 Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
PCT/EP2001/005211 WO2001085174A1 (en) 2000-05-12 2001-05-08 Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases

Publications (1)

Publication Number Publication Date
BG107257A true BG107257A (bg) 2003-06-30

Family

ID=11445031

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107257A BG107257A (bg) 2000-05-12 2002-11-08 Състави, съдържащи глюкокортикоидно средство за лечение на бронхо-белодробни заболявания

Country Status (21)

Country Link
US (1) US20030190289A1 (bg)
EP (1) EP1280532A1 (bg)
JP (1) JP2004515454A (bg)
AR (1) AR028448A1 (bg)
AU (1) AU2001258395A1 (bg)
BG (1) BG107257A (bg)
CA (1) CA2408647A1 (bg)
CZ (1) CZ20023717A3 (bg)
EA (1) EA200201059A1 (bg)
EE (1) EE200200632A (bg)
HR (1) HRP20020893A2 (bg)
HU (1) HUP0302036A2 (bg)
IT (1) IT1318514B1 (bg)
MA (1) MA26899A1 (bg)
MX (1) MXPA02011132A (bg)
NO (1) NO20025394L (bg)
PE (1) PE20011271A1 (bg)
PL (1) PL366212A1 (bg)
SK (1) SK16062002A3 (bg)
TN (1) TNSN01071A1 (bg)
WO (1) WO2001085174A1 (bg)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
JP5392880B2 (ja) * 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
ES2222294T3 (es) * 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
EP3384931B1 (en) * 2002-03-01 2019-07-24 Chiesi Farmaceutici S.p.A. Formoterol superfine formulation
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
RU2568882C2 (ru) * 2010-07-16 2015-11-20 Сипла Лимитед Фармацевтические композиции
WO2015195711A2 (en) * 2014-06-16 2015-12-23 Shurtleff, James, Kevin Method and devices for manufacturing and delivering of aerosolized formulations
CN116421585B (zh) * 2023-05-09 2025-03-11 苏州欧米尼医药有限公司 一种混悬型布地奈德吸入气雾剂及其制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) * 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3622053A (en) * 1969-12-10 1971-11-23 Schering Corp Aerosol inhaler with flip-up nozzle
US4185100A (en) * 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
US4499108A (en) * 1983-06-08 1985-02-12 Schering Corporation Stable pleasant-tasting albuterol sulfate pharmaceutical formulations
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
US4584320A (en) * 1985-01-03 1986-04-22 David Rubin Anti-asthmatic composition and method using 8,11,14,17-eicosatetraenoic acid
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US6006745A (en) * 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
CA2116579A1 (en) * 1991-08-29 1993-03-18 Christoph Klein Medical device for inhaling doses of spray
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
DE4230876A1 (de) * 1992-03-17 1993-09-23 Asta Medica Ag Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten
SK280911B6 (sk) * 1992-12-09 2000-09-12 Boehringer Ingelheim Pharmaceuticals, Inc. Farmaceutický prostriedok
SE9203743D0 (sv) * 1992-12-11 1992-12-11 Astra Ab Efficient use
WO1994014490A1 (de) * 1992-12-23 1994-07-07 Bernhard Hugemann Verfestigter arzneistoffvorrat für die mechanische erzeugung inhalierbarer wirkstoffpartikel
CA2178473C (en) * 1993-12-20 2004-08-24 Tsi-Zong Tzou Flunisolide aerosol formulations
US5653961A (en) * 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
AP791A (en) * 1995-04-14 1999-12-17 Glaxo Wellcome Inc Metered dose inhaler for albuterol.
KR19980703850A (ko) * 1995-04-14 1998-12-05 그레이엄브레레톤 베클로메타손 디프로피오네이트용 계량 흡입기
MX9707862A (es) * 1995-04-14 1997-11-29 Glaxo Wellcome Inc Inhalador de dosis medida para el propionato de fluticasona.
MX9707864A (es) * 1995-04-14 1997-11-29 Glaxo Wellcome Inc Inhalador de dosis medida por salmeterol.
JP2728057B2 (ja) * 1995-10-30 1998-03-18 日本電気株式会社 光ディスク用情報アクセス装置
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
US6413496B1 (en) * 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US5954047A (en) * 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
US6045784A (en) * 1998-05-07 2000-04-04 The Procter & Gamble Company Aerosol package compositions containing fluorinated hydrocarbon propellants
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
JP4570251B2 (ja) * 1998-07-24 2010-10-27 ヤゴテック アーゲー 医薬用エーロゾル製剤
DE19847969A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
AU756852B2 (en) * 1998-11-13 2003-01-23 Jagotec Ag Dry powder for inhalation
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6290930B1 (en) * 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
ES2286881T3 (es) * 1999-03-05 2007-12-01 Chiesi Farmaceutici S.P.A. Composiciones farmaceuticas en polvo mejoradas para inhalacion.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
JP5392880B2 (ja) * 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
EP3384931B1 (en) * 2002-03-01 2019-07-24 Chiesi Farmaceutici S.p.A. Formoterol superfine formulation
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects

Also Published As

Publication number Publication date
SK16062002A3 (sk) 2003-04-01
ITMI20001051A1 (it) 2001-11-12
US20030190289A1 (en) 2003-10-09
EP1280532A1 (en) 2003-02-05
NO20025394D0 (no) 2002-11-11
PE20011271A1 (es) 2002-01-11
IT1318514B1 (it) 2003-08-27
TNSN01071A1 (fr) 2005-11-10
EE200200632A (et) 2004-04-15
HUP0302036A2 (hu) 2003-09-29
ITMI20001051A0 (it) 2000-05-12
WO2001085174A1 (en) 2001-11-15
MXPA02011132A (es) 2003-04-25
JP2004515454A (ja) 2004-05-27
AR028448A1 (es) 2003-05-07
PL366212A1 (en) 2005-01-24
CZ20023717A3 (cs) 2003-04-16
NO20025394L (no) 2003-01-13
HRP20020893A2 (en) 2004-02-29
AU2001258395A1 (en) 2001-11-20
EA200201059A1 (ru) 2003-04-24
MA26899A1 (fr) 2004-12-20
CA2408647A1 (en) 2001-11-15

Similar Documents

Publication Publication Date Title
ATE308317T1 (de) Zubereitungen mit einem anticholinergischen wirkstoff für die behandlung der chronischen obstruktiven lungenerkrankung
BG107257A (bg) Състави, съдържащи глюкокортикоидно средство за лечение на бронхо-белодробни заболявания
AU4260496A (en) Propellant mixture for aerosol formulation
CA2125665A1 (en) Medicaments
YU59899A (sh) Medicinski aerosolni proizvodi
RU94030722A (ru) Аэрозольная фармацевтическая композиция, лекарственное средство с модифицированной поверхностью, баллон для доставки фармацевтической композиции, ингалятор, способ лечения респираторных заболеваний
NZ243061A (en) Aerosol containing a medicament and 1,1,1,2,3,3,3-heptafluoropropane
MX9300620A (es) Formulacion farmaceutica en aerosol e inhalador para la administracion de dipropionato de beclometasona.
ES2123576T3 (es) Medicamentos.
ATE391501T1 (de) Aerosoldosiergeräte für delta 9 tetrahydrocannabinol (delta 9 thc)zusammensetzungen und verwendungsverfahren
AR018410A1 (es) Uso de una composicion para la manufactura de un medicamento que se usa para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitentey/o episodios de asma cronico y metodo para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitente y/o episodios de asma cron
WO2002011711A3 (en) Formulations of mometasone and a bronchodilator for pulmonary administration
MY130946A (en) Medicinal inhalation aerosol formulations containing budesonide
EG22790A (en) A device for the administration of pressurized metered dose aerosols in hydrofluoroalkane propellants
AU2003215588A1 (en) Aerosol formulations containing esters of 3,17-dihydroxy oestratriene derivatives for pulmonary delivery
TH59260A3 (th) การให้สารออกฤทธิ์ที่ได้รับการทำเป็นแอโรซอล
MX9604004A (es) Formualciones de farmaco en aerosol que contienen vitamina e.